Join the 200th Anniversary Celebration

Original Article

Long-Term Survival of Children with End-Stage Renal Disease

Stephen P. McDonald, Ph.D., and Jonathan C. Craig, Ph.D. for the Australian and New Zealand Paediatric Nephrology Association

N Engl J Med 2004; 350:2654-2662June 24, 2004

Abstract

Background

Although renal-replacement therapy for children with end-stage renal disease has been used for several decades, data on patients' long-term survival are sparse.

Methods

We examined the long-term survival of all children and adolescents who were under 20 years of age when renal-replacement therapy commenced (study period, April 1963 through March 2002), using data from the Australia and New Zealand Dialysis and Transplant Registry. Survival was analyzed with the use of Kaplan–Meier methods and age-standardized mortality rates. Risk factors for death were analyzed with the use of Cox regression analysis with time-dependent covariates.

Results

A total of 1634 children and adolescents were followed for a median of 9.7 years. The long-term survival rate among children requiring renal-replacement therapy was 79 percent at 10 years and 66 percent at 20 years. Mortality rates were 30 times as high as for children without end-stage renal disease. Risk factors for death were a young age at the time renal-replacement therapy was initiated (especially for children under 1 year of age, among whom the risk was four times as high as for children 15 to 19 years of age) and treatment with dialysis (which was associated with a risk more than four times as high as for renal transplantation). Overall, a trend toward improved survival was observed over the four decades of the study.

Conclusions

Despite improvement in long-term survival, mortality rates among children requiring renal-replacement therapy remain substantially higher than those among children without end-stage renal disease. Increasing the proportion of children treated with renal transplantation rather than with dialysis can improve survival further.

Media in This Article

Figure 1Kaplan–Meier Graphs of Overall Rates of Survival among Children and Adolescents with End-Stage Renal Disease in Australia and New Zealand from 1963 to 2002, According to Age and Decade during Which Treatment Began.
Figure 2Hazard Ratios for Death among Children and Adolescents with End-Stage Renal Disease in Australia and New Zealand, According to Selected Predictive Variables.
Article

End-stage renal disease, which is a rare but important health problem among children, occurs in about 5 to 10 children per million each year.1 The disease is a chronic condition; even renal transplantation does not mean lifelong cure. Quality-of-life studies have shown that life without native kidney function is very difficult for children and their families.2

Forty years ago, children with end-stage renal disease died. Now, almost all such children are treated with dialysis or renal transplantation. Treatment typically involves multiple therapies, depending upon the availability of kidneys for transplantation and the long-term survival of the transplants. Long-term survival rates among children with end-stage renal disease are uncertain, and there are few data to inform patients, families, clinicians, and policymakers about survival. The available studies are generally short-term,3-6 are based on single-center experiences,7 and include only information with regard to patients receiving dialysis, patients undergoing transplantation, or patients in specific age groups.8

The Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry has prospectively collected data on all children in whom renal-replacement therapy was started in Australia or New Zealand beginning in 1963. Using data from this registry, we examined long-term survival among children treated for end-stage renal disease and identified modifiable and unmodifiable risk factors for death.

Methods

Study Design

We performed a prospective inception-cohort study from the time renal-replacement therapy was initiated for all children and adolescents younger than 20 years of age in Australia and New Zealand who were registered in the ANZDATA Registry. The registry collects information every six months from all the renal units in Australia and New Zealand about all patients receiving renal-replacement therapy who have a diagnosis of chronic renal failure and for whom indefinite renal-replacement therapy is intended. Details regarding the registry have been reported elsewhere.9

The data collection is complete from the first use of renal-replacement therapy in Australia and New Zealand and includes information on the cause of end-stage renal disease, demographic characteristics of the patients, a limited range of coexisting conditions (which since 1991 have included coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, hypertension, and smoking), and details of dialysis treatment and renal transplantation. Nephrologists are asked to provide a cause of death for children who have died, but death certificates are not directly reviewed by the ANZDATA Registry.

The consent and privacy provisions of the ANZDATA Registry have evolved over time and currently require informed consent from patients or a parent or legal guardian and include a right of access to personal information.9 The registry is conducted in accordance with the Australian Commonwealth Privacy Act and associated state legislation governing health data collection. The anonymity of patient information is maintained by the coding of data during compilation; only information with personal identifiers removed is released by the registry.

All patients who were younger than 20 years of age when renal-replacement therapy commenced and whose first treatment occurred before April 1, 2002, were included in our analysis. Patients were followed until death or until March 31, 2002, whichever occurred first. Children who regained native renal function permanently despite their initial assessment were excluded; data on those lost to follow-up were censored as of the date of the last follow-up visit. The sole outcome examined was death, ascertained with the use of the registry data.

Statistical Analysis

The time from the start of renal-replacement therapy to death or the date on which the data were censored was analyzed with the use of the Kaplan–Meier method and Cox proportional-hazards models. Standardized mortality rate ratios and age-specific mortality rate ratios were calculated for Australian children only, with the use of contemporary life-expectancy values derived from life tables of the Australian Bureau of Statistics.

A multivariate Cox proportional-hazards model was constructed with age, sex, the decade in which renal-replacement therapy was initiated, primary renal disease, and type of dialysis (hemodialysis or peritoneal dialysis) as predictive variables. A categorical, time-dependent covariate was used for the type of renal-replacement therapy (hemodialysis, peritoneal dialysis, or transplantation) to allow for changes in type of therapy over time. Age and the year in which renal-replacement therapy was started were considered as categories in order to avoid the assumption of linear relationships with outcome. Age was analyzed in five-year categories, except for children younger than one year of age, who were considered as a separate group because they have a worse prognosis.3,4,6,10 Inclusion in the final model was determined by a backward stepwise process with the use of the likelihood ratio to evaluate the effect of omitting variables. Stata statistical software (version 7.0, Stata) was used for the analysis; a P value of 0.05 was considered to indicate statistical significance, and 95 percent confidence intervals are provided when relevant.

Results

Demographic Characteristics

Between April 1, 1963, and March 31, 2002, 1634 children and adolescents under 20 years of age commenced renal-replacement therapy in Australia or New Zealand (Table 1Table 1Number of Children Treated for End-Stage Renal Disease in Australia and New Zealand in the Period from 1963 to 2002, According to Age and Decade of Initial Treatment.). Of these patients, 917 were boys (56 percent). A total of 18,392 person-years of follow-up were available. Of these, 4072 person-years took place during hemodialysis treatment (including 1435 person-years, or 35 percent, in the form of hemodialysis at home), 1633 person-years of peritoneal dialysis (including 1473 person-years, or 90 percent, in the form of of peritoneal dialysis at home), and 12,686 person-years with a functioning renal transplant. Data on 32 children (2 percent) were censored as of the date of the last follow-up visit, owing to loss to follow-up (primarily as a result of relocation overseas). The median period of follow-up was 9.7 years (range, 1 month to 35 years; interquartile range, 4.1 to 17.6 years).

The number of children over five years of age when renal-replacement therapy is initiated has been constant since the mid-1980s, but the number under five years of age at the start of therapy has increased. Reported causes of end-stage renal disease were consistent with those in other studies and varied with age. Congenital problems predominated among younger children, and reflux nephropathy and glomerulonephritis among older children. Twenty-six percent of children who were younger than 5 years of age when renal-replacement therapy commenced had renal hypoplasia and dysplasia, as compared with 5 percent of those who were 10 to 19 years of age when the therapy was initiated. In children younger than five years of age at the initiation of renal-replacement therapy, only 11 percent had glomerulonephritis and 3 percent had reflux nephropathy. In contrast, 44 percent of children 10 to 19 years of age had glomerulonephritis and 25 percent had reflux nephropathy.

Mode of Treatment

Among the 1634 children, 1398 (86 percent) received 1 or more renal transplants (of 1939 transplantations, 136 were of grafts that were transplanted into patients who had not previously received dialysis treatment, or preemptive grafts, and 3 were performed outside Australia or New Zealand). Overall, the median waiting time from the initiation of renal-replacement therapy among the 515 children whose first allograft was from a living donor was 137 days (interquartile range, 10 to 382), and the median waiting time was 402 days (interquartile range, 192 to 785) among those whose first graft was a cadaveric allograft. The proportion of allografts from living donors has steadily increased over time — from 5 percent to 21 percent, 35 percent, and 64 percent among children commencing renal-replacement therapy in the decades 1963 to 1972, 1973 to 1982, 1983 to 1992, and 1993 to 2002, respectively. Median times from the initiation of renal-replacement therapy to the first transplantation among patients who received dialysis for a period were 161, 334, 324, and 296 days among children who commenced renal-replacement therapy in the decades 1963 to 1972, 1973 to 1982, 1983 to 1992, and 1993 to 2002, respectively. Monoclonal- or polyclonal-antibody therapy for prophylaxis against rejection was used after transplantation of 319 allografts (16 percent).

The proportion of children receiving renal transplantation as renal-replacement therapy has remained steady over time. More older children tended to be treated with dialysis than with renal transplantation. Among children in our study, the median duration of hemodialysis was 1.7 years (interquartile range, 0.5 to 4.3), that of peritoneal dialysis 1.1 years (interquartile range, 0.4 to 2.5), and that of a functioning transplant 7.4 years (interquartile range, 2.7 to 14.3).

Overall Survival and Causes of Death

During the study period there were 436 deaths: 142 deaths occurred in patients with a functioning renal transplant, 97 in patients who were receiving peritoneal dialysis, and 197 in patients who were receiving hemodialysis. The most common cause of death was cardiovascular disease (45 percent), and the second most common cause was infection (21 percent). Of the deaths due to cardiovascular causes, 25 percent were attributed to cardiac arrest (cause uncertain), 16 percent to cerebrovascular accident, 14 percent to myocardial ischemia, 12 percent to pulmonary edema, 11 percent to hyperkalemia, and 22 percent to other cardiovascular causes.

The cause of death varied with the type of renal-replacement therapy — cardiovascular causes accounted for 57 percent of deaths among children receiving hemodialysis, 43 percent among those receiving peritoneal dialysis, and only 30 percent among those with a functioning renal transplant. In contrast, malignant diseases were responsible for 14 percent of deaths among children who had a functioning transplant, but only 1 percent of deaths among patients receiving hemodialysis and 2 percent among those receiving peritoneal dialysis. Death from malignant disease generally occurred late, accounting for only 1 percent of deaths in the first four years after renal-replacement therapy was initiated and 2 percent five to nine years after the start of renal-replacement therapy. In contrast, malignant disease accounted for 13 percent of deaths that occurred 10 to 14 years after the start of renal-replacement therapy and 17 percent of deaths 15 or more years after its start.

The proportion of deaths attributed to infection has declined over time, from 39 percent (12 of 31 deaths) between 1963 and 1972 to 16 percent (26 of 163) between 1993 and 2002. Across age groups, cardiovascular death accounted for 20 percent of deaths (2 of 10) among children younger than 1 year of age at the start of renal-replacement therapy, 24 percent (6 of 25) among those 1 to 4 years of age at its start, but 47 percent among those 5 to 9 years of age at the start of renal-replacement therapy (23 of 49), 44 percent among those 10 to 14 years of age at its start (48 of 110), and 48 percent among those 15 to 19 years of age at its start (117 of 242).

Rates of survival after 5, 10, 15, and 20 years of renal-replacement therapy are shown in Table 2Table 2Unadjusted Long-Term Survival among Children with End-Stage Renal Disease in Australia and New Zealand, According to Age at the Start of Renal-Replacement Therapy.. Contemporary Australian population data indicate that the expected 20-year survival among children is greater than 97 percent at all ages11; however, for this cohort with end-stage renal disease, mortality greatly exceeded the population rates in all age groups (Table 3Table 3Age-Specific Rate Ratios for Death within 10 Years among Children Who Started Renal-Replacement Therapy in Australia in the Period from 1963 to 2002, as Compared with Age-Specific Mortality among the General Australian Population.).

Rates of long-term survival among infants as compared with older children with end-stage renal disease appear worse, particularly in the first five years after the initiation of renal-replacement therapy (Table 2). After a substantial improvement in survival occurred in most age groups in the years from 1963 to 1973, and further improvement from 1973 to 1983, less change occurred from 1983 onward (Figure 1Figure 1Kaplan–Meier Graphs of Overall Rates of Survival among Children and Adolescents with End-Stage Renal Disease in Australia and New Zealand from 1963 to 2002, According to Age and Decade during Which Treatment Began.). In data categorized by calendar year, the death rates were 11.0 (95 percent confidence interval, 7.9 to 15.4) per 100 patient-years between 1963 and 1972, 4.4 (95 percent confidence interval, 3.7 to 5.3) per 100 patient-years between 1973 and 1982, 2.0 (95 percent confidence interval, 1.7 to 2.4) per 100 patient-years between 1983 and 1992, and 1.8 (95 percent confidence interval, 1.5 to 2.1) per 100 patient-years since 1993.

Rates of survival also varied with the type of renal-replacement therapy. Overall mortality rates were 4.8 (95 percent confidence interval, 4.2 to 5.6) per 100 patient-years among patients receiving hemodialysis, 5.9 (95 percent confidence interval, 4.9 to 7.2) per 100 patient-years among those receiving peritoneal dialysis, and 1.1 (95 percent confidence interval, 0.9 to 1.3) per 100 patient-years among those with a functioning renal transplant.

Multivariate analysis suggested that a younger age at the start of renal-replacement therapy, receiving dialysis rather than renal transplantation, and commencing renal-replacement therapy before 1983 were associated with an increased risk of death. There was a weak interaction between transplantation and the decade in which renal-replacement therapy was started (P=0.07), but the benefit associated with transplantation at all times was similar (Figure 2Figure 2Hazard Ratios for Death among Children and Adolescents with End-Stage Renal Disease in Australia and New Zealand, According to Selected Predictive Variables.).

Delay before Transplantation

Delay in kidney transplantation as a potential risk factor for early death was analyzed by comparing mortality among groups with different lengths of time until transplantation. To account for survival bias, delay as a predictor of early death was analyzed beginning two years after the initiation of renal-replacement therapy. There was no significant difference in mortality observed among those who survived to two years among groups with different lengths of time until transplantation (Figure 3Figure 3Kaplan–Meier Graph of Survival Rates among Children and Adolescents in Australia and New Zealand Who Survived at Least Two Years after the Start of Renal-Replacement Therapy, According to the Length of Time to Transplantation.).

Discussion

Our data indicate that a substantial improvement in the long-term survival of children and adolescents with end-stage renal disease occurred over the past 40 years. The experimental nature of the use of dialysis and transplantation among children during the decade from 1963 to 1972 provides a partial explanation, given that the improvement in mortality subsequently slowed. Ten-year survival remains about 80 percent, and age-specific mortality is about 30 times as high as among children without end-stage renal disease.

These mortality rates are similar to those reported in a U.S. study for the period from 1990 to 199612 but are slightly higher than those reported in a Dutch study of a smaller cohort13 that did not include adolescents. The distribution of primary renal disease and the mortality rates among patients receiving dialysis in our study are similar to those in recent reports from the North American Pediatric Renal Transplant Collaborative Study (NAPRTCS), in which the duration of follow-up was shorter for a cohort of pediatric dialysis patients.6 The causes of death reflect the excess risk of cardiac disease and vascular disease and the high prevalence of left ventricular hypertrophy and dyslipidemia among children treated with renal-replacement therapy.14-16 The number of deaths from cardiovascular disease among the patients who received dialysis in our study was higher than that reported by the U.S. Renal Data System (37 percent)17 and by the NAPRTCS (21 percent).18 Detailed comparisons, however, are hindered by the different coding systems used in the various studies, especially the different definitions of diagnoses coded “unknown” and “other.”

The trend toward improvement in the rates of survival among patients in our study has also been observed since 1987 among patients in the NAPRTCS Registry who have undergone renal transplantation.18 The 2003 NAPRTCS report18 noted that the overall rate of survival to 36 months was 96.6 percent among recipients of kidney transplants from living donors and 94.8 percent among those receiving cadaveric kidneys — values similar to the 1.1 percent annual mortality rate we observed among transplant recipients. The strengths of our study — the large number of children in the study, prospective data collection, the availability of accurate data on the type of renal-replacement therapy, and the long duration of follow-up with minimal loss to follow-up — enabled us to provide valid and reasonably precise estimates of long-term survival and to identify modifiable and unmodifiable risk factors for death.

The year in which renal-replacement therapy was initiated, the age of patients at the start of renal-replacement therapy, and the type of dialysis used were associated with the risk of death. Our data suggest that the older a child is when renal-replacement therapy is required, the better his or her chances for long-term survival. This improved survival may be due to the less aggressive nature of the underlying renal disease process, to the fact that associated coexisting conditions are more likely to occur in infants and young children, or to the greater technical challenges of delivering renal-replacement therapy to young and small children.

Perhaps more important is our finding that dialysis is associated with a risk of death that is four times the risk associated with renal transplantation. The improvement in survival after renal transplantation is substantial and sustained. This finding is consistent with the relative survival advantage among adults who have undergone transplantation, as shown in studies conducted in Australia and New Zealand19 and in the United States.20 The proportion of children with end-stage renal disease who are treated with transplantation can be increased by increasing the number of kidneys available for transplantation (that is, by increasing rates of donation from living donors or by preferentially allocating cadaveric kidneys to children) and by means of improvements in the preservation of the renal function of allografts. These interventions are being attempted widely, with some variation among and within countries. Others have shown a survival advantage in the short term among children who receive “preemptive” transplants from living donors before the need for dialysis arises.5

We did not find that a longer period of dialysis before transplantation was detrimental to survival after transplantation. However, there was limited statistical power in the present study for this comparison. Although we looked at survival only among children who survived longer than two years after the onset of end-stage renal disease, some residual survival bias may account for this lack of difference; the ANZDATA Registry does not collect enough details about coexisting conditions for us to adjust fully for this potential effect. Nevertheless, patients who have a longer wait for renal transplantation will have worse overall outcomes, because they are exposed for a longer period to the increased risk of death that is associated with dialysis treatment. This fact is a clear incentive to increase the rates of transplantation among children with end-stage renal disease.

There was a low rate of loss to follow-up in the cohort. Informally, the ANZDATA Registry data are believed to be accurate: information is checked against available data from tissue-typing and organ-donation sources, but formal audit mechanisms were not in place during the period we studied. Data on deaths were not checked against death certificates; a previous study that matched the registry's data on deaths with national death-certificate reports21 has confirmed that mortality (though not necessarily cause) was accurately ascertained.

The current study has weaknesses. The ANZDATA Registry does not record details of patients with end-stage renal disease who are not treated, and treatment thresholds have clearly been lowered over time, particularly among children. These changing thresholds are likely to be reflected in both referral and selection biases — that is, sicker children were less likely to be referred for renal-replacement therapy and, after they are referred, are less likely to be offered such treatment. These biases would lead to the underestimation of improvements in outcome over time, with an increasing tendency toward treating sicker children. Attitudes among nephrologists toward offering renal-replacement therapy to very young children vary considerably.22 Although the qualifications of treating physicians are not specifically collected by the registry, patients under 20 years of age in Australia and New Zealand are treated almost exclusively by pediatric nephrologists in specialist pediatric centers. Other information about details of treatment in the registry are limited. Data on hemoglobin concentrations and the use of erythropoietic agents have been collected only since 2000, and data on lipid levels and blood pressure are not collected. The use of growth hormone has been sparse; approximately one third of children in Australia and less than 10 percent in New Zealand have received growth hormone.1

Any misclassifications of data with regard to exposure or outcome are likely to be nondifferential with respect to study periods and types of treatment; thus, our findings regarding associations between the type of treatment and outcomes are conservative. The time-dependent covariates used in our model result in the attribution of death to the type of renal-replacement therapy in use immediately before death. This method may result in an overestimation of the benefit of transplantation, since deaths that occurred among patients receiving dialysis but that were related to the recent failure of a renal transplant were attributed to the use of dialysis. Another obvious source of bias in the comparison of outcomes between dialysis and transplantation is the selection of the healthier patients to undergo transplantation, although the high proportion of patients in our study cohort who received a renal transplant suggests this effect is relatively minor.

Our data indicate that long-term survival can be expected for most children with end-stage renal disease. Transplantation remains the major modifiable factor in improving the long-term survival of children and adults with this disease. Early transplantation appears indicated to prevent exposure to the increased risks associated with dialysis therapy. Yet mortality rates among children who undergo transplantation remain in excess of those in the normal population. The challenge ahead is to reduce the incidence of the cardiovascular and malignant diseases that account for the bulk of long-term mortality among children with end-stage renal disease.

Supported by the Australian Government Department of Health and Ageing, the New Zealand Department of Health, and Kidney Health Australia (formerly the Australian Kidney Foundation).

Dr. McDonald reports having received lecture fees from Amgen Australia and Janssen-Cilag Australia; he is employed by ANZDATA, and although he receives no direct industrial support, part of his salary is funded by a grant from Amgen Australia to the ANZDATA Registry, which also receives grant support from Janssen-Cilag Australia, Novartis, Wyeth Australia, and Fresenius. Dr. Craig reports having received grants from Janssen-Cilag Australia, Novartis, Amgen Australia, Wyeth Australia, and Fresenius.

We are indebted to the staff of all Australian and New Zealand renal units for their efforts in data collection (the ANZDATA Registry exists because of their dedicated efforts), and to Steven Morrell of the School of Public Health at the University of Sydney for help with the age-specific mortality rates.

Source Information

From the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Queen Elizabeth Hospital, Adelaide, Australia (S.P.M.); and the Centre for Kidney Research and the National Health and Medical Research Council Centre for Clinical Research Excellence in Renal Medicine, Children's Hospital at Westmead, and the School of Public Health, University of Sydney — all in Sydney (J.C.C.).

Address reprint requests to Dr. McDonald at the ANZDATA Registry, Queen Elizabeth Hospital, 28 Woodville Rd., Woodville South SA 5011, Australia, or at .

References

References

  1. 1

    Walker RG. Paediatric report. In: Disney APS, ed. The twenty-second report: Australia and New Zealand Dialysis and Transplant Registry 1999. Adelaide, Australia: ANZDATA Registry, 1999:90-97.

  2. 2

    Henning P, Tomlinson L, Rigden SP, Haycock GB, Chantler C. Long term outcome of treatment of end stage renal failure. Arch Dis Child 1988;63:35-40
    CrossRef | Web of Science | Medline

  3. 3

    Ehrich JH, Rizzoni G, Brunner FP, et al. Renal replacement therapy for end-stage renal failure before 2 years of age. Nephrol Dial Transplant 1992;7:1171-1177
    Web of Science | Medline

  4. 4

    Wood EG, Hand M, Briscoe DM, et al. Risk factors for mortality in infants and young children on dialysis. Am J Kidney Dis 2001;37:573-579
    CrossRef | Web of Science | Medline

  5. 5

    Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS study. Transplantation 2000;69:1414-1419
    CrossRef | Web of Science | Medline

  6. 6

    Leonard MB, Donaldson LA, Ho M, Geary DF. A prospective cohort study of incident maintenance dialysis in children: an NAPRTC study. Kidney Int 2003;63:744-755
    CrossRef | Web of Science | Medline

  7. 7

    Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden SJ, Trompeter RS. Long-term outcome of peritoneal dialysis in infants. J Pediatr 2000;136:24-29
    CrossRef | Web of Science | Medline

  8. 8

    Coulthard MG, Crosier J. Outcome of reaching end stage renal failure in children under 2 years of age. Arch Dis Child 2002;87:511-517
    CrossRef | Web of Science | Medline

  9. 9

    Russ GR. Australia and New Zealand Dialysis and Transplant Registry Report 2002. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2002.

  10. 10

    Held PJ, Turenne MN, Liska DW, et al. Treatment modality patterns and transplantation among the United States pediatric end-stage renal disease population: a longitudinal study. In: Terasaki P, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992:71-85.

  11. 11

    Deaths: Australia, 2000. Canberra, Australia: Australian Bureau of Statistics, 2001. (ABS catalogue no. 3302.0.)

  12. 12

    Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002;141:191-197
    CrossRef | Web of Science | Medline

  13. 13

    Groothoff JW, Gruppen MP, Offringa M, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 2002;61:621-629
    CrossRef | Web of Science | Medline

  14. 14

    Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000;14:898-902
    CrossRef | Web of Science | Medline

  15. 15

    Bakkaloglu SA, Ekim M, Tumer N, Soylu K. The effect of CAPD on the lipid profile of pediatric patients. Perit Dial Int 2000;20:568-571
    Web of Science | Medline

  16. 16

    Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB, Baluarte HJ. Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol 2000;14:105-110
    CrossRef | Web of Science | Medline

  17. 17

    Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, 2003.

  18. 18

    North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2003 Annual report: renal transplantation, dialysis, chronic renal insufficiency. Rockville, Md.: EMMES, 2003.

  19. 19

    McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrol Dial Transplant 2002;17:2212-2219
    CrossRef | Web of Science | Medline

  20. 20

    Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-1730
    Full Text | Web of Science | Medline

  21. 21

    Li SQ, Cass A, Cunningham J. Cause of death in patients with end-stage renal disease: assessing concordance of death certificates with registry reports. Aust N Z J Public Health 2003;27:419-424
    CrossRef | Web of Science | Medline

  22. 22

    Geary DF. Attitudes of pediatric nephrologists to management of end-stage renal disease in infants. J Pediatr 1998;133:154-156
    CrossRef | Web of Science | Medline

Citing Articles (124)

Citing Articles

  1. 1

    M. D. Sinha, L. Kerecuk, J. Gilg, C. J. D. Reid, . (2012) Systemic arterial hypertension in children following renal transplantation: prevalence and risk factors. Nephrology Dialysis Transplantation
    CrossRef

  2. 2

    Stephen A. Stayer, Glynn Williams, Dean B. Andropoulos. 2012. Anesthesia for Transplantation. , 678-719.
    CrossRef

  3. 3

    M. D. Sinha, J. A. Gilg, L. Kerecuk, C. J. D. Reid, . (2012) Progression to hypertension in non-hypertensive children following renal transplantation. Nephrology Dialysis Transplantation
    CrossRef

  4. 4

    Stuart L. Goldstein. (2012) Acute Kidney Injury in Children and Its Potential Consequences in Adulthood. Blood Purification 33:1-3, 131-137
    CrossRef

  5. 5

    A. Peco-Antic, R. Bogdanovic, D. Paripovic, A. Paripovic, N. Kocev, E. Golubovic, B. Milosevic, . (2011) Epidemiology of chronic kidney disease in children in Serbia. Nephrology Dialysis Transplantation
    CrossRef

  6. 6

    Susan M. Halbach, Karen Martz, Tej Mattoo, Joseph Flynn. (2011) Predictors of Blood Pressure and Its Control in Pediatric Patients Receiving Dialysis. The Journal of Pediatrics
    CrossRef

  7. 7

    Emma Allain-Launay, Gwénaëlle Roussey-Kesler. (2011) Insuffisance rénale chronique de l’enfant. La Presse Médicale 40:11, 1028-1036
    CrossRef

  8. 8

    B. J. Foster, M. Dahhou, X. Zhang, R. W. Platt, J. A. Hanley. (2011) Change in Mortality Risk Over Time in Young Kidney Transplant Recipients. American Journal of Transplantation 11:11, 2432-2442
    CrossRef

  9. 9

    W. F. Tromp, N. J. Schoenmaker, J. H. van der Lee, B. Adams, A. H. M. Bouts, L. Collard, K. Cransberg, R. Van Damme-Lombaerts, N. Godefroid, K. van Hoeck, L. Koster-Kamphuis, M. R. Lilien, A. Raes, M. Offringa, J. W. Groothoff. (2011) Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study. Nephrology Dialysis Transplantation
    CrossRef

  10. 10

    Claus Peter Schmitt, Otto Mehls. (2011) Mineral and bone disorders in children with chronic kidney disease. Nature Reviews Nephrology 7:11, 624-634
    CrossRef

  11. 11

    Franz Schaefer, Bradley A. Warady. (2011) Peritoneal dialysis in children with end-stage renal disease. Nature Reviews Nephrology 7:11, 659-668
    CrossRef

  12. 12

    Rukshana Shroff, Donald J. Weaver, Mark M. Mitsnefes. (2011) Cardiovascular complications in children with chronic kidney disease. Nature Reviews Nephrology 7:11, 642-649
    CrossRef

  13. 13

    Dominik Müller, Stuart L. Goldstein. (2011) Hemodialysis in children with end-stage renal disease. Nature Reviews Nephrology 7:11, 650-658
    CrossRef

  14. 14

    Rene G. VanDeVoorde, Mark M. Mitsnefes. (2011) Hypertension and CKD. Advances in Chronic Kidney Disease 18:5, 355-361
    CrossRef

  15. 15

    Lars Pape, Frank Lehner, Cornelia Blume, Thurid Ahlenstiel. (2011) Pediatric Kidney Transplantation Followed by De Novo Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data. Transplantation 92:6, 658-662
    CrossRef

  16. 16

    Ahmed Mohammed Mosaad, Ahmed Farouk Aziz Hamdy, Nabil Mohamed Abd El-Fattah Hassan, Mohamed Ashraf Fouda, Khaled Mohamed Mahmoud, Mohamed El-Sayed Salem, El-Metwally Lotfy El-Shahawy, Ahmed Shokeir, Mohamed Adel Bakr, Mohamed Ahmed Ghoneim. (2011) Evaluation of live-donor kidney transplant survival in low body weight Egyptian children: 25 year-experience. Diálisis y Trasplante
    CrossRef

  17. 17

    Jérôme Harambat, Karlijn J. Stralen, Jon Jin Kim, E. Jane Tizard. (2011) Epidemiology of chronic kidney disease in children. Pediatric Nephrology
    CrossRef

  18. 18

    Rukshana Shroff, Catherine Quinlan, Mark Mitsnefes. (2011) Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?. Pediatric Nephrology 26:6, 853-865
    CrossRef

  19. 19

    Stephanie Nguyen, Karen Martz, Don Stablein, Alicia Neu. (2011) Wait list status of pediatric dialysis patients in North America. Pediatric Transplantation 15:4, 376-383
    CrossRef

  20. 20

    Rukshana Shroff. (2011) Dysregulated mineral metabolism in children with chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:3, 233-240
    CrossRef

  21. 21

    Toyofumi Abe, Naotsugu Ichimaru, Yoichi Kakuta, Masayoshi Okumi, Ryoichi Imamura, Yoshitaka Isaka, Shiro Takahara, Yukito Kokado, Akihiko Okuyama. (2011) Long-term outcome of pediatric renal transplantation: a single center experience. Clinical Transplantation 25:3, 388-394
    CrossRef

  22. 22

    Jennifer Heath, Dorothy MacKinlay, Alan R. Watson, Anna Hames, Lucy Wirz, Sarah Scott, Elaine Klewchuk, David Milford, Kathleen McHugh. (2011) Self-reported quality of life in children and young people with chronic kidney disease. Pediatric Nephrology 26:5, 767-773
    CrossRef

  23. 23

    Stuart L. Goldstein, Prasad Devarajan. (2011) Acute kidney injury in childhood: should we be worried about progression to CKD?. Pediatric Nephrology 26:4, 509-522
    CrossRef

  24. 24

    Joshua Zaritsky, Bradley A. Warady. (2011) Peritoneal Dialysis in Infants and Young Children. Seminars in Nephrology 31:2, 213-224
    CrossRef

  25. 25

    Renata C. Marciano, Cristina M. Bouissou Soares, José Silvério S. Diniz, Eleonora M. Lima, Jose Maria P. Silva, Monica R. Canhestro, Andrea Gazzinelli, Carla Cristina D. Melo, Cristiane S. Dias, Ana Cristina Simões e Silva, Humberto Correa, Eduardo A. Oliveira. (2011) Behavioral disorders and low quality of life in children and adolescents with chronic kidney disease. Pediatric Nephrology 26:2, 281-290
    CrossRef

  26. 26

    L.T. Weber. (2011) Pädiatrisch nephrologische Erkrankungen nach dem Transfer. Der Nephrologe 6:1, 9-21
    CrossRef

  27. 27

    C. P. Schmitt, A. Zaloszyc, B. Schaefer, M. Fischbach. (2011) Peritoneal Dialysis Tailored to Pediatric Needs. International Journal of Nephrology 2011, 1-9
    CrossRef

  28. 28

    Jeffrey M Saland, Christopher B Pierce, Mark M Mitsnefes, Joseph T Flynn, Jens Goebel, Juan C Kupferman, Bradley A Warady, Susan L Furth. (2010) Dyslipidemia in children with chronic kidney disease. Kidney International 78:11, 1154-1163
    CrossRef

  29. 29

    Robert J. Brooks, Gail Y. Higgins, Angela C. Webster. (2010) Systematic review of randomized controlled trial quality in pediatric kidney transplantation. Pediatric Nephrology 25:12, 2383-2392
    CrossRef

  30. 30

    Ashton Chen, Karen Martz, David Kershaw, John Magee, Panduranga S. Rao. (2010) Mortality risk in children after renal allograft failure: a NAPRTCS study. Pediatric Nephrology 25:12, 2517-2522
    CrossRef

  31. 31

    Marco Cavallini, Giacomo Zazzo, Ugo Giordano, Giacomo Pongiglione, Luca Dello Strologo, Nicola Capozza, Francesco Emma, Maria Chiara Matteucci. (2010) Long-term cardiovascular effects of pre-transplant native kidney nephrectomy in children. Pediatric Nephrology 25:12, 2523-2529
    CrossRef

  32. 32

    Trine Tangeraas, Karsten Midtvedt, Per Morten Fredriksen, Milada Cvancarova, Lars Mørkrid, Anna Bjerre. (2010) Cardiorespiratory fitness is a marker of cardiovascular health in renal transplanted children. Pediatric Nephrology 25:11, 2343-2350
    CrossRef

  33. 33

    P. J. Goldsmith, S. Asthana, M. Fitzpatrick, E. Finlay, M. S. Attia, K. V. Menon, S. G. Pollard, D. M. Ridgway, N. Ahmad. (2010) Transplantation of adult-sized kidneys in low-weight pediatric recipients achieves short-term outcomes comparable to size-matched grafts. Pediatric Transplantation 14:7, 919-924
    CrossRef

  34. 34

    Aftab S. Chishti, Stefan G. Kiessling. (2010) Adults who had kidney disease in childhood. International Journal on Disability and Human Development 9:2-3, 177-181
    CrossRef

  35. 35

    Poyyapakkam R. SRIVATHS, Douglas M. SILVERSTEIN, Jocelyn LEUNG, Rajesh KRISHNAMURTHY, Stuart L. GOLDSTEIN. (2010) Malnutrition-inflammation-coronary calcification in pediatric patients receiving chronic hemodialysis. Hemodialysis International 14:3, 263-269
    CrossRef

  36. 36

    ANGELA C WEBSTER, RAJAH SUPRAMANIAM, DIANNE L O'CONNELL, JEREMY R CHAPMAN, JONATHAN C CRAIG. (2010) Validity of registry data: Agreement between cancer records in an end-stage kidney disease registry (voluntary reporting) and a cancer register (statutory reporting). Nephrology 15:4, 491-501
    CrossRef

  37. 37

    Samantha J. Anthony, Stacey Pollock BarZiv, Vicky Lee Ng. (2010) Quality of Life After Pediatric Solid Organ Transplantation. Pediatric Clinics of North America 57:2, 559-574
    CrossRef

  38. 38

    C. Rinat, R. Becker-Cohen, A. Nir, S. Feinstein, D. Shemesh, N. Algur, E. Ben Shalom, B. Farber, Y. Frishberg. (2010) A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrology Dialysis Transplantation 25:3, 785-793
    CrossRef

  39. 39

    B. Tönshoff. (2010) Allokation von Nierentransplantaten. Der Nephrologe 5:S1, 36-44
    CrossRef

  40. 40

    Samantha J. Anthony, Diane Hebert, Laura Todd, Moira Korus, Valerie Langlois, Rita Pool, Lisa A. Robinson, Angela Williams, Stacey M. Pollock-BarZiv. (2010) Child and parental perspectives of multidimensional quality of life outcomes after kidney transplantation. Pediatric Transplantation 14:2, 249-256
    CrossRef

  41. 41

    Amy C. Wilson, Larry A. Greenbaum, Gina M. Barletta, Deepa Chand, Jen-Jar Lin, Hiren P. Patel, Mark Mitsnefes. (2010) High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatric Transplantation 14:1, 52-60
    CrossRef

  42. 42

    Oyedolamu K. Olaitan, Jose A. Zimmermann, William P. Shields, Guillermo Rodriguez-Navas, Atif Awan, Ponnusamy Mohan, Dilly M. Little, David P. Hickey. (2010) Long-term outcome of intensive initial immunosuppression protocol in pediatric deceased donor renal transplantation. Pediatric Transplantation 14:1, 87-92
    CrossRef

  43. 43

    B. Hocker, L. T. Weber, R. Feneberg, J. Drube, U. John, H. Fehrenbach, M. Pohl, M. Zimmering, S. Frund, G. Klaus, E. Wuhl, B. Tonshoff. (2010) Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrology Dialysis Transplantation 25:2, 617-624
    CrossRef

  44. 44

    Yiu-fai Cheung. 2010. Systemic Circulation. , 91-116.
    CrossRef

  45. 45

    Makoto Mizutani, Hiroko Chikamoto, Hiroaki Ueda, Kimiko Taniguchi, Yuko Kajiho, Masayuki Furuyama, Kiyonobu Ishizuka, Mamiko Suehiro, Hiroshi Fujii, Masataka Hisano, Yuko Akioka, Osamu Segawa, Shouhei Fuchinoue, Satoshi Teraoka, Motoshi Hattori. (2010) Clinical features of Autosomal recessive polycystic kidney disease-a single-center experience-. Nihon Shoni Jinzobyo Gakkai Zasshi 23:2, 123-127
    CrossRef

  46. 46

    Hiren P. Patel. (2010) Early Origins of Cardiovascular Disease in Pediatric Chronic Kidney Disease. Renal Failure 32:1, 1-9
    CrossRef

  47. 47

    Daryl M. Okamura, Jonathan Himmelfarb. (2009) Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatric Nephrology 24:12, 2309-2319
    CrossRef

  48. 48

    Susan M. Koshy, Astrid Guttmann, Diane Hebert, Robert K. Parkes, Alexander G. Logan. (2009) Incidence and risk factors for cardiovascular events and death in pediatric renal transplant patients: A single center long-term outcome study. Pediatric Transplantation 13:8, 1027-1033
    CrossRef

  49. 49

    (2009) Evidence-based Practice Guideline for the Treatment of CKD. Clinical and Experimental Nephrology 13:6, 537-566
    CrossRef

  50. 50

    Stuart L. Goldstein. (2009) Physical functioning in children with end-stage renal disease: Small steps first. Pediatric Transplantation 13:7, 802-804
    CrossRef

  51. 51

    Jonathan Himmelfarb. (2009) Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy. Seminars in Dialysis 22:6, 636-643
    CrossRef

  52. 52

    Stuart L. Goldstein. (2009) Physical Fitness in Children With End-Stage Renal Disease. Advances in Chronic Kidney Disease 16:6, 430-436
    CrossRef

  53. 53

    Allison Tong, Rachael Morton, Kirsten Howard, Jonathan C. Craig. (2009) Adolescent Experiences Following Organ Transplantation: A Systematic Review of Qualitative Studies. The Journal of Pediatrics 155:4, 542-549.e5
    CrossRef

  54. 54

    Michelle N. Rheault, Jurat Rajpal, Blanche Chavers, Thomas E. Nevins. (2009) Outcomes of infants <28 days old treated with peritoneal dialysis for end-stage renal disease. Pediatric Nephrology 24:10, 2035-2039
    CrossRef

  55. 55

    Nigel I. T. Orr, Stephen P. McDonald, Steven McTaggart, Paul Henning, Jonathan C. Craig. (2009) Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand. Pediatric Nephrology 24:9, 1719-1726
    CrossRef

  56. 56

    E. Allain-Launay, G. Roussey-Kesler, B. Ranchin, G. Guest, A. Maisin, R. Novo, J. L. André, S. Cloarec, C. Guyot. (2009) Mortality in pediatric renal transplantation: A study of the French pediatric kidney database. Pediatric Transplantation 13:6, 725-730
    CrossRef

  57. 57

    Amy C. Wilson, Mark M. Mitsnefes. (2009) Cardiovascular Disease in CKD in Children: Update on Risk Factors, Risk Assessment, and Management. American Journal of Kidney Diseases 54:2, 345-360
    CrossRef

  58. 58

    Stuart L. Goldstein, Nicole M. Rosburg, Bradley A. Warady, Mouin Seikaly, Ruth McDonald, Christine Limbers, James W. Varni. (2009) Pediatric end stage renal disease health-related quality of life differs by modality: a PedsQL ESRD analysis. Pediatric Nephrology 24:8, 1553-1560
    CrossRef

  59. 59

    Isolina Riaño-Galán, Serafín Málaga, Luis Rajmil, Gema Ariceta, Mercedes Navarro, Cesar Loris, Alfredo Vallo. (2009) Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatric Nephrology 24:8, 1561-1568
    CrossRef

  60. 60

    Rana Hijazi, Carolyn L. Abitbol, Jayanthi Chandar, Wacharee Seeherunvong, Michael Freundlich, Gastón Zilleruelo. (2009) Twenty-five Years of Infant Dialysis: A Single Center Experience. The Journal of Pediatrics 155:1, 111-117
    CrossRef

  61. 61

    Alicia M. Neu, Diane L. Frankenfield. (2009) Clinical outcomes in pediatric hemodialysis patients in the USA: lessons from CMS’ ESRD CPM Project. Pediatric Nephrology 24:7, 1287-1295
    CrossRef

  62. 62

    Susan M. Koshy, Diane Hebert, Kelvin Lam, Therese A. Stukel, Astrid Guttmann. (2009) Renal Allograft Loss During Transition to Adult Healthcare Services Among Pediatric Renal Transplant Patients. Transplantation 87:11, 1733-1736
    CrossRef

  63. 63

    Mirjam Harmsen, Eddy M.M. Adang, René J. Wolters, Johannes C. van der Wouden, Richard P.T.M. Grol, Michel Wensing. (2009) Management of Childhood Urinary Tract Infections: An Economic Modeling Study. Value in Health 12:4, 466-472
    CrossRef

  64. 64

    Poyyapakkam R. Srivaths, Craig Wong, Stuart L. Goldstein. (2009) Nutrition aspects in children receiving maintenance hemodialysis: impact on outcome. Pediatric Nephrology 24:5, 951-957
    CrossRef

  65. 65

    Jutta Muscheites, Marianne Wigger, Erdmute Drueckler, Ilka Klaassen, Ulrike John, Simone Wygoda, Dagmar-Christiane Fischer, Guenther Kundt, Joachim Misselwitz, Dirk-E Müller-Wiefel, Dieter Haffner. (2009) Estimated one-yr glomerular filtration rate is an excellent predictor of long-term graft survival in pediatric first kidney transplants. Pediatric Transplantation 13:3, 365-370
    CrossRef

  66. 66

    Marc R. Lilien, Jaap W. Groothoff. (2009) Cardiovascular disease in children with CKD or ESRD. Nature Reviews Nephrology 5:4, 229-235
    CrossRef

  67. 67

    Stuart L. Goldstein, Lance R. Montgomery. (2009) A pilot study of twice-weekly exercise during hemodialysis in children. Pediatric Nephrology 24:4, 833-839
    CrossRef

  68. 68

    B. M. Chavers, J. J. Snyder, M. A. Skeans, E. D. Weinhandl, B. L. Kasiske. (2009) Racial Disparity Trends for Graft Failure in the US Pediatric Kidney Transplant Population, 1980-2004. American Journal of Transplantation 9:3, 543-549
    CrossRef

  69. 69

    Rukshana Shroff, Sarah Ledermann. (2009) Long-term outcome of chronic dialysis in children. Pediatric Nephrology 24:3, 463-474
    CrossRef

  70. 70

    Lesley Rees. (2009) Long-term outcome after renal transplantation in childhood. Pediatric Nephrology 24:3, 475-484
    CrossRef

  71. 71

    Robert H. Mak. (2009) Recent advances in chronic dialysis and renal transplantation in children. Pediatric Nephrology 24:3, 459-461
    CrossRef

  72. 72

    Britta Höcker, Lutz T. Weber, Reinhard Feneberg, Jens Drube, Ulrike John, Henry Fehrenbach, Martin Pohl, Miriam Zimmering, Stefan Fründ, Günter Klaus, Elke Wühl, Burkhard Tönshoff. (2009) Prospective, Randomized Trial on Late Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine Microemulsion and Mycophenolate Mofetil. Transplantation 87:6, 934-941
    CrossRef

  73. 73

    B. Tönshoff. (2009) Allokation von Nierentransplantaten für pädiatrische Patienten. Der Nephrologe 4:1, 59-60
    CrossRef

  74. 74

    Donald J. Weaver, Mark M. Mitsnefes. (2009) Inflammation and cardiovascular complications in chronic kidney disease. Journal of Organ Dysfunction 5:4, 208-217
    CrossRef

  75. 75

    Julia Becker, Wolf-Dietrich Huber, Christoph Aufricht. (2008) Short- and long-time effects of pediatric liver transplantation on serum cholesterol and triglyceride levels - The Vienna Cohort. Pediatric Transplantation 12:8, 883-888
    CrossRef

  76. 76

    Mesiha Ekim, Sevcan A. Bakkaloglu, Nejat Aksu, Sema Akman, Aytul Noyan, Lale Sever. (2008) Challenges in pediatric peritoneal dialysis in Turkey. International Urology and Nephrology 40:4, 1027-1033
    CrossRef

  77. 77

    D. L. Gillen, C. O. Stehman-Breen, J. M. Smith, R. A. McDonald, B. A. Warady, J. R. Brandt, C. S. Wong. (2008) Survival Advantage of Pediatric Recipients of a First Kidney Transplant Among Children Awaiting Kidney Transplantation. American Journal of Transplantation 8:12, 2600-2606
    CrossRef

  78. 78

    A. Kramer, V. S. Stel, J. Tizard, E. Verrina, K. Ronnholm, R. Palsson, H. Maxwell, K. J. Jager. (2008) Characteristics and survival of young adults who started renal replacement therapy during childhood. Nephrology Dialysis Transplantation 24:3, 926-933
    CrossRef

  79. 79

    Antonio Santoro, Elena Mancini, Roberto Bolzani, Rolando Boggi, Leonardo Cagnoli, Angelo Francioso, Maurizio Fusaroli, Valter Piazza, Renato Rapanà, Giovanni F.M. Strippoli. (2008) The Effect of On-line High-flux Hemofiltration Versus Low-flux Hemodialysis on Mortality in Chronic Kidney Failure: A Small Randomized Controlled Trial. American Journal of Kidney Diseases 52:3, 507-518
    CrossRef

  80. 80

    Rachel Becker-Cohen, Amiram Nir, Efrat Ben-Shalom, Choni Rinat, Sofia Feinstein, Benjamin Farber, Yaacov Frishberg. (2008) Improved left ventricular mass index in children after renal transplantation. Pediatric Nephrology 23:9, 1545-1550
    CrossRef

  81. 81

    Jutta Falger, Markus A. Landolt, Bea Latal, Eva M. Rüth, Thomas J. Neuhaus, Guido F. Laube. (2008) Outcome after renal transplantation. Part II: Quality of life and psychosocial adjustment. Pediatric Nephrology 23:8, 1347-1354
    CrossRef

  82. 82

    Jutta Falger, Bea Latal, Markus A. Landolt, Phaedra Lehmann, Thomas J. Neuhaus, Guido F. Laube. (2008) Outcome after renal transplantation. Part I: Intellectual and motor performance. Pediatric Nephrology 23:8, 1339-1345
    CrossRef

  83. 83

    Deepa H. Chand, Rudolph P. Valentini. (2008) International Pediatric Fistula First Initiative: A Call to Action. American Journal of Kidney Diseases 51:6, 1016-1024
    CrossRef

  84. 84

    Lesley Rees. (2008) Management of the neonate with chronic renal failure. Seminars in Fetal and Neonatal Medicine 13:3, 181-188
    CrossRef

  85. 85

    Dennis A Hesselink, Ron HN van Schaik, Jeroen Nauta, Teun van Gelder. (2008) A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics 9:6, 783-789
    CrossRef

  86. 86

    Jonathan C. Craig. (2008) Kidney Transplantation in Children: The Preferred Option But Still No Cure. American Journal of Kidney Diseases 51:6, 880-881
    CrossRef

  87. 87

    Franz Schaefer. (2008) Cardiac disease in children with mild-to-moderate chronic kidney disease. Current Opinion in Nephrology and Hypertension 17:3, 292-297
    CrossRef

  88. 88

    Helena Ziolkowska, Michal Brzewski, Maria Roszkowska-Blaim. (2008) Determinants of the intima–media thickness in children and adolescents with chronic kidney disease. Pediatric Nephrology 23:5, 805-811
    CrossRef

  89. 89

    Sharon M. Bartosh, Frederick C. Ryckman, Robert Shaddy, Marian G. Michaels, Jeffrey L. Platt, Stuart C. Sweet. (2008) A national conference to determine research priorities in pediatric solid organ transplantation. Pediatric Transplantation 12:2, 153-166
    CrossRef

  90. 90

    Stuart L. Goldstein, Nicole Graham, Bradley A. Warady, Mouin Seikaly, Ruth McDonald, Tasha M. Burwinkle, Christine A. Limbers, James W. Varni. (2008) Measuring Health-Related Quality of Life in Children With ESRD: Performance of the Generic and ESRD-Specific Instrument of the Pediatric Quality of Life Inventory (PedsQL). American Journal of Kidney Diseases 51:2, 285-297
    CrossRef

  91. 91

    Jyoti Gupta, Sandra Amaral, William T. Mahle. (2008) Renal Transplantation After Previous Pediatric Heart Transplantation. The Journal of Heart and Lung Transplantation 27:2, 217-221
    CrossRef

  92. 92

    Joana E. Kist-van Holthe, David M. Briscoe, Vikas R. Dharnidharka. 2008. Management of End-Stage Renal Disease in Childhood and Adolescence. , 522-535.
    CrossRef

  93. 93

    Ramanath N. Haricharan, Charles J. Aprahamian, Traci L. Morgan, Carroll M. Harmon, Douglas C. Barnhart. (2008) Intermediate-term patency of upper arm arteriovenous fistulae for hemodialysis access in children. Journal of Pediatric Surgery 43:1, 147-151
    CrossRef

  94. 94

    Mark M. Mitsnefes. (2007) Cardiovascular complications of pediatric chronic kidney disease. Pediatric Nephrology 23:1, 27-39
    CrossRef

  95. 95

    Bradley A. Warady, Vimal Chadha. (2007) Chronic kidney disease in children: the global perspective. Pediatric Nephrology 22:12, 1999-2009
    CrossRef

  96. 96

    M. Naesens, N. Kambham, W. Concepcion, O. Salvatierra, M. Sarwal. (2007) The Evolution of Nonimmune Histological Injury and Its Clinical Relevance in Adult-Sized Kidney Grafts in Pediatric Recipients. American Journal of Transplantation 7:11, 2504-2514
    CrossRef

  97. 97

    Stuart L. Goldstein, Arlene C. Gerson, Susan Furth. (2007) Health-Related Quality of Life for Children With Chronic Kidney Disease. Advances in Chronic Kidney Disease 14:4, 364-369
    CrossRef

  98. 98

    Steven D. Weisbord, Janet B. McGill, Paul L. Kimmel. (2007) Psychosocial Factors in Patients With Chronic Kidney Disease. Advances in Chronic Kidney Disease 14:4, 316-318
    CrossRef

  99. 99

    Jeffrey M. Saland, Henry N. Ginsberg. (2007) Lipoprotein metabolism in chronic renal insufficiency. Pediatric Nephrology 22:8, 1095-1112
    CrossRef

  100. 100

    C. K. Abeysekera, W. D. V. N. Gunasekara, A. Abegunawardena, A. G. Buthpitiya, M. D. Lamawansa, O. Fernando, C. D. A. Goonasekera. (2007) First experiences of pediatric kidney transplantation in Sri Lanka. Pediatric Transplantation 11:4, 408-413
    CrossRef

  101. 101

    Caroline K. Lee, Laura L. Christensen, John C. Magee, Akinlolu O. Ojo, William E. Harmon, Nancy D. Bridges. (2007) Pre-transplant Risk Factors for Chronic Renal Dysfunction After Pediatric Heart Transplantation: A 10-Year National Cohort Study. The Journal of Heart and Lung Transplantation 26:5, 458-465
    CrossRef

  102. 102

    Steven McTaggart. (2007) Calcineurin inhibitors in paediatric renal transplantation. Nephrology 12:s1, S106-S110
    CrossRef

  103. 103

    Mohamed Alaa Thabet, James C. M. Chan. (2006) Vitamin E in renal therapeutic regimens. Pediatric Nephrology 21:12, 1790-1801
    CrossRef

  104. 104

    Giovanni FM Strippoli, Allison Tong, Suetonia C Palmer, Grahame J Elder, Jonathan C Craig, Giovanni FM Strippoli. 2006. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. .
    CrossRef

  105. 105

    Giovanni FM Strippoli, Sankar D Navaneethan, Jonathan C Craig, Suetonia C Palmer, Giovanni FM Strippoli. 2006. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. .
    CrossRef

  106. 106

    Sean E. Kennedy, Fiona E. Mackie, Andrew R. Rosenberg, Stephen P. McDonald. (2006) Waiting Time and Outcome of Kidney Transplantation in Adolescents. Transplantation 82:8, 1046-1050
    CrossRef

  107. 107

    Sahar A. Fathallah-Shaykh, Ellen R. Brooks, Craig B. Langman, Kenneth R. Kensey. (2006) Sodium modeling attenuates rises in whole-blood viscosity during chronic hemodialysis in children with large inter-dialytic weight gain. Pediatric Nephrology 21:8, 1179-1184
    CrossRef

  108. 108

    Maria E. Ferris, Debbie S. Gipson, Paul L. Kimmel, Paul W. Eggers. (2006) Trends in treatment and outcomes of survival of adolescents initiating end-stage renal disease care in the United States of America. Pediatric Nephrology 21:7, 1020-1026
    CrossRef

  109. 109

    Thomas Becker, Michael Neipp, Benedikt Reichart, Lars Pape, Jochen Ehrich, Jurgen Klempnauer, Gisela Offner. (2006) Paediatric kidney transplantation in small children - a single centre experience. Transplant International 19:3, 197-202
    CrossRef

  110. 110

    Stuart L. Goldstein, Arlene C. Gerson, Cheri W. Goldman, Susan Furth. (2006) Quality of Life for Children With Chronic Kidney Disease. Seminars in Nephrology 26:2, 114-117
    CrossRef

  111. 111

    Gregory Gorman, Susan Furth, Wenke Hwang, Rulan Parekh, Brad Astor, Barbara Fivush, Diane Frankenfield, Alicia Neu. (2006) Clinical Outcomes and Dialysis Adequacy in Adolescent Hemodialysis Patients. American Journal of Kidney Diseases 47:2, 285-293
    CrossRef

  112. 112

    Rukshana Shroff, Lesley Rees, Richard Trompeter, Carol Hutchinson, Sarah Ledermann. (2006) Long-term outcome of chronic dialysis in children. Pediatric Nephrology 21:2, 257-264
    CrossRef

  113. 113

    Alicia M. Neu. (2006) Special Issues in Pediatric Kidney Transplantation. Advances in Chronic Kidney Disease 13:1, 62-69
    CrossRef

  114. 114

    J.A. Stockman. (2006) Long-term Survival of Children With End-Stage Renal Disease. Yearbook of Pediatrics 2006, 201-203
    CrossRef

  115. 115

    B. Winkelmann, J. Thumfart, D. Müller, M. Giessing, A. Wille, S. Deger, D. Schnorr, U. Querfeld, S. Loening, J. Roigas. (2006) Nierentransplantation im Kindes- und Jugendalter. Der Urologe 45:1, 18-24
    CrossRef

  116. 116

    Giovanni F.M. Strippoli, Jonathan C. Craig. (2005) Hypothesis Versus Association: The Optimal Hemoglobin Target Debate. American Journal of Kidney Diseases 46:5, 970-973
    CrossRef

  117. 117

    Vimal Chadha, Bradley A. Warady. (2005) Epidemiology of Pediatric Chronic Kidney Disease. Advances in Chronic Kidney Disease 12:4, 343-352
    CrossRef

  118. 118

    Daniela Miklovicova, Marlies Cornelissen, Karlien Cransberg, Jaap W. Groothoff, Ladislav Dedik, Cornelis H. Schrőder. (2005) Etiology and epidemiology of end-stage renal disease in Dutch children 1987–2001. Pediatric Nephrology 20:8, 1136-1142
    CrossRef

  119. 119

    Michael B. Ishitani, Dawn S. Milliner, Dean Y. Kim, Humberto E. Bohorquez, Julie K. Heimbach, Patrick F. Sheedy, Bruce Z. Morgenstern, James M. Gloor, Joseph G. Murphy, Robert D. McBane, Lawrence F. Bielak, Patricia A. Peyser, Mark D. Stegall. (2005) Early Subclinical Coronary Artery Calcification in Young Adults Who Were Pediatric Kidney Transplant Recipients. American Journal of Transplantation 5:7, 1689-1693
    CrossRef

  120. 120

    J. W. Groothoff. (2005) Long-term outcomes of children with end-stage renal disease. Pediatric Nephrology 20:7, 849-853
    CrossRef

  121. 121

    Fabienne Dobbels, Rita Van Damme-Lombaert, Johan Vanhaecke, Sabina De Geest. (2005) Growing pains: Non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatric Transplantation 9:3, 381-390
    CrossRef

  122. 122

    Christoph Troppmann, Maureen A. McBride, Timothy J. Baker, Richard V. Perez. (2005) Laparoscopic Live Donor Nephrectomy: A Risk Factor for Delayed Function and Rejection in Pediatric Kidney Recipients? A UNOS Analysis. American Journal of Transplantation 5:1, 175-182
    CrossRef

  123. 123

    Stephen MCDONALD. (2004) Indigenous transplant outcomes in Australia: What the ANZDATA Registry tells us. Nephrology 9:s4, S138-S143
    CrossRef

  124. 124

    Milliner, Dawn S., . (2004) Pediatric Renal-Replacement Therapy — Coming of Age. New England Journal of Medicine 350:26, 2637-2639
    Full Text